RxDoctor Payments Data

Arathi Rana, MD

Dermatology · Galveston, TXNPI 1306291125

Payments from drug & device makers

$2,945in general payments, 2019–2025

Across 128 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • LEO Pharma Inc.$423
  • Lilly USA, LLC$289
  • Sun Pharmaceutical Industries Inc.$235
  • Johnson & Johnson$213
  • Galderma Laboratories, L.p.$183
  • plus $549 from 13 others

What the payments were for

  • Food & beverage$2,945100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,945 in reported general payments places this provider in the 40th percentile of 1,098 dermatology providers in Texas.

See all dermatology providers in Texas

Medicare billing

Part B allowed, 2024
$520,758
Medicare patients
1,533
Services billed
9,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab49$206,310
OtezlaApremilast24$115,671
Betamethasone Dipropionate87$4,277
Clobetasol Propionate45$2,864
Triamcinolone Acetonide191$2,340
Doxycycline Monohydrate47$2,295
Ketoconazole85$1,380
Metronidazole33$1,270
Mometasone Furoate36$817
Doxycycline Hyclate17$631
Fluorouracil11$576
Fluocinonide20$559
Hydrocortisone68$452
Clindamycin Phosphate12$361
Econazole Nitrate11$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$123$115,67124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,098 dermatology providers in Texas.

Other dermatology in Galveston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →